Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 2,590 Cr.
- Current Price ₹ 562
- High / Low ₹ 645 / 435
- Stock P/E 82.3
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 11.5 %
- ROE 25.2 %
- Face Value ₹ 10.0
Pros
Cons
- Company might be capitalizing the interest cost
- Company has high debtors of 191 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 14 | 35 | 215 | |
| 12 | 23 | 173 | |
| Operating Profit | 2 | 13 | 42 |
| OPM % | 14% | 36% | 19% |
| 0 | 4 | 3 | |
| Interest | 1 | 2 | 9 |
| Depreciation | 1 | 2 | 10 |
| Profit before tax | 1 | 12 | 25 |
| Tax % | 13% | 32% | -31% |
| 1 | 8 | 33 | |
| EPS in Rs | 1.01 | 8.59 | 10.31 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 507% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 273% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 9 | 10 | 31 |
| Reserves | 28 | 36 | 174 |
| 15 | 63 | 258 | |
| 8 | 23 | 160 | |
| Total Liabilities | 59 | 131 | 622 |
| 7 | 27 | 235 | |
| CWIP | 8 | 34 | 97 |
| Investments | 15 | 16 | 0 |
| 29 | 53 | 289 | |
| Total Assets | 59 | 131 | 622 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -10 | -1 | -20 | |
| -24 | -48 | -54 | |
| 36 | 46 | 87 | |
| Net Cash Flow | 2 | -3 | 13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 506 | 228 | 191 |
| Inventory Days | 135 | 89 | 129 |
| Days Payable | 324 | 388 | 389 |
| Cash Conversion Cycle | 317 | -71 | -70 |
| Working Capital Days | 414 | 316 | 181 |
| ROCE % | 18% | 12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Senores Pharmaceuticals acquires ANDA for Roflumilast tablets.
-
Intimation For Change In The Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of The Company.
18 Feb - Change in domain name and email of RTA.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 Feb - Senores Pharmaceuticals Limited has informed about Schedule of meet.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 Jan - Senores Pharmaceuticals Limited has informed regarding transcript of Earnings Conference Call held on January 23, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Jan - Senores Pharmaceuticals Limited has informed regarding Newspaper Publications- Un-audited Financial Results of the Company pursuant to Regulation 30 and 47 of the SEBI (LODR) Regulations, …
Concalls
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs